By 2020, we aim to enroll suppliers covering 80% of our spend in our Sustainable Procurement Program. By 2019, we had enrolled suppliers covering 71% of spend in the program. We also aim to consistently achieve benchmark spending with US diverse and small suppliers. In 2019, we exceeded benchmark diverse supplier spending at 11% and benchmark small supplier spending at 18% of total U.S. spend.
In our efforts to identify a potential COVID-19 vaccine candidate, in 2020 we initiated our multi-country Phase 3 trial, ENSEMBLE, designed to evaluate the safety and efficacy of a single dose of our investigational COVID-19 vaccine candidate versus placebo in up to 60,000 adults. In parallel, we also initiated the two-dose regiment ENSEMBLE 2 trial, a multi-country Phase 3 trial to study the safety and efficacy of a two-dose regimen of our investigational vaccine candidate for the prevention of COVID-19 in up to 30,000 participants worldwide. We are committed to providing transparent updates throughout the clinical development process of our investigational vaccine candidate.
We are scaling up capacity and remain on track to meet a goal of supplying at a rate of more than one billion doses of the vaccine globally by the end of 2021. Johnson & Johnson is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.
In 2020, we founded and are co-leading the Corona Accelerated R&D in Europe consortium, bringing together Europe’s brightest scientific minds, as well as partners in the United States and China to achieve therapeutic breakthroughs against SARS-CoV-2, the virus that causes COVID-19 disease.
In 2018, we announced a 10-year tuberculosis goal of saving an estimated 1.8 million lives and preventing 12 million new infections. This includes a commitment of $500 million dedicated to research & development and delivery programs between 2018-2022 to accelerate global efforts to eliminate tuberculosis by 2030.
In July 2020, we announced a $100 million commitment to the AMR Action Fund, a collaboration with more than 20 leading pharmaceutical companies to collectively invest nearly $1 billion to address AMR. The Action Fund’s goal is to bring two to four new antibiotics to patients by the end of the decade.
We have committed to sourcing 100% of our electricity needs from renewable sources by 2025. Our accelerated progress with renewable electricity procurement over the past five years has given us the confidence to accelerate this goal from our previous commitment of 2050 to 2025.
By 2030 we aim to achieve carbon neutrality in our operations (Scope 1 & 2 emissions) globally. This goal puts us on track to exceed what the science tells us is necessary for our business to contribute towards a 1.5-degree Celsius decarbonization roadmap.
We will work with our suppliers to aim to reduce our upstream carbon footprint by 20% by 2030. We will launch new workstreams in carbon intensive procurement categories including logistics, chemicals, external manufacturing and packaging, among others.
This Scope 3 goal aims to deliver nearly 2.5 times the carbon footprint reduction compared to that for our own operations.
In 2020, we announced BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority, a component of the U.S. Department of Health and Human Services (BARDA), that aims to stimulate and accelerate innovation to improve global health security.
As part of BLUE KNIGHT, seven initial companies were selected for their promising work to fill the gaps in the current set of available COVID-19 solutions. Selected BLUE KNIGHT resident start-up companies receive fee assistance for certain costs associated with access to JLABS equipment and resources, and mentorship from the Johnson & Johnson Family of Companies as well as BARDA. Additional applications for BLUE KNIGHT residency will be accepted on a rolling basis.
In 2020, Johnson & Johnshon launched the Center for Health Worker Innovation (CHWI) to address the World Health Organization’s projected shortage of more than 18 million frontline health workers by 2030. The Johnson & Johnson Family of Companies and the Johnson & Johnson Foundation made a $250 million commitment, guided by CHWI, to support one million nurses, midwives and community health workers by 2030.
In March 2020, this commitment was increased by an additional $50 million to support frontline health workers in the global fight against COVID-19 – from meals to protective equipment, extra training to mental health.
Starting in 2020, we will commit $10 million over three years to fight systemic racism in America. We will identify and announce partnerships with organizations that we believe will make the biggest difference in advancing social justice, with a focus on the urgent need to address the inequities in medical care that have long plagued minority communities.
Johnson & Johnson is working with partners to identify sustainable solutions to combat intestinal worms longer term. These include improving diagnostics for STH and providing funding to support the development of national monitoring and evaluation frameworks to allow for better data collection, more informed decision-making, and ultimately, targeted therapeutic interventions that have the potential to control intestinal worms in endemic countries.
In 2020, Johnson & Johnson committed $100 million over the next five years to invest in and promote health equity solutions for Black people and other communities of color in the United States. This commitment prioritizes three key areas: Healthier Communities – investing in programs that help provide equitable healthcare for underserved communities; Enduring Alliances – forging partnerships and alliances that combat racial and social health determinants; and Diverse & Inclusive Corporate Culture – ensuring a diverse and inclusive workforce.
We will make multi-million-dollar investments in Healthier Communities and Enduring Alliances programs, while the investment made in our Diverse & Inclusive Corporate Culture will largely focus on enhancing processes, training, and education. Although this announcement represents immediate action, Johnson & Johnson’s commitment to address racial and social injustice is enduring.
Johnson & Johnson is focused on cultivating a diverse and inclusive workforce that inspires innovative healthcare solutions around the world. In 2020, we committed to hiring more diverse employees, with a goal of achieving 50% growth of our Black and African American talent at the manager and above levels in the United States over the next five years. We are also enhancing our HR processes to optimize accessing, hiring and developing talent, along with offering cultural immersion programs to enhance awareness and understanding.
Established in 2019, our Enterprise Human Rights Governance Council aims to strengthen our continued engagement with Shift on developing sustainable approaches to implementing the UN Guiding Principles on Business and Human Rights.
Together with other companies, policymakers, academic organizations and advocacy partners, Johnson & Johnson is taking action to facilitate greater dialogue among under-represented communities to help address systemic inequities, such as unconscious and conscious bias, language barriers, overall trial design and access to funding that can help build trust around increased participation in clinical trials.
We must work together to ensure broader representation of diverse populations in clinical trials to enhance the benefits of medical innovation and close the gap of inequity in order to pave the way to a healthier future for everyone everywhere.
We are leveraging a digital and community engagement strategy in our Company-sponsored COVID-19 clinical trials to help increase representation of diverse populations in clinical research, identifying and implementing ways to reduce operational barriers and patient burden, applying lessons from other trial recruitment efforts, and educating diverse communities across the United States about clinical trials and the importance of participation.
Continue to ensure we have the appropriate structures, systems and processes in place to enable access to the medicines and technologies most relevant for underserved populations in low- and middle-income countries.
In the last decade, Johnson & Johnson has consistently ranked among the top three companies worldwide working to expand access to medicine, according to the Access to Medicine Index. And our Global Public Health unit is a model in the industry on access planning and results for several therapeutic areas—while constantly challenging itself to do more.
We are committed to delivering HIV/AIDS therapy access to a cumulative 130,000 adults and 5,000 children by the end of 2020.
Along with partners, we are broadening access to HIV treatment, including empowering youth in South Africa to reduce the spread of HIV and expanding global access to HIV antiretroviral therapy for children (partners: U.S. President’s Emergency Plan for AIDS Relief).
By 2025, we are committed to donate one billion doses of VERMOX® CHEWABLE intestinal worms treatment to at-risk children in developing countries. Intestinal worms are the most widespread of neglected tropical diseases and have a particularly damaging impact on the health and development of children.
We aim to become the healthiest workforce by 2020, spanning spiritual, mental, emotional, physical and financial health.
Progress thus far includes:
Our ongoing commitment to providing leadership development programs for high-potential, diverse talent develops highly capable leaders and connects senior leaders to diverse individuals for development.
For our employees who completed RISE (Accelerated Program for Racially and Ethnically Diverse Talent) or ASCEND (Accelerated Development Program for Women) in 2019, 33% have had a promotion or lateral movement in either the year of attendance of after.
Johnson & Johnson commits to support employees in building digital acumen and a better understanding of technology in key areas that include data science, automation and digital experience through digital skills training and our Data Science Academy, which launched in 2019.
Our annual WiSTEM2D Scholars Award fuels the development of female STEM2D leaders and inspires career paths in STEM2D. The award is granted to an assistant or associate academic professor around the world in science, technology, engineering, math, manufacturing and/or design; the recipient receives $50,000 each year for three years and mentorship from leaders at Johnson & Johnson.
Our ongoing partnership with the U.S. National Center for Women and Information Technology supports leading academic centers by providing mentorships, internships, training and reward programs for female students.
We commit to grow the global footprint of our Re-Ignite returnship program to support and empower employees with expertise in STEM, Manufacturing and Design (STEM2D) and with a two-year or longer career break to transition back to the workplace.
Through our external innovation model, which includes four Innovation Centers in major life science hubs on three continents, we are committed to supporting the life science ecosystem. We executed 65+ deals in 2019 and deployed $145+ million in capital on new deals.
Johnson & Johnson Innovation – JLABS, our open-innovation ecosystem for healthcare (consumer, medical device, biopharmaceutical and health tech) supports entrepreneurs and startups with 13 facilities in the United States, Canada, Belgium and China.
To date, more than 650 companies have been supported via JLABS. Approximately 59% of our residents are first-time entrepreneurs. 30% of companies are led by women, and 29% are led by minorities.
In the United States, we are committed to donating medicines and funding to the Johnson & Johnson Patient Assistance Foundation Inc. (JJPAF), an independent, nonprofit organization committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. In 2019, we donated $1.2 billion in free product and financial support to JJPAF, enabling the Foundation to provide medicines at no cost to approximately 82,000 patients.
Johnson & Johnson has a track record of investing R&D resources in and supporting access to treatment to effectively combat soil-transmitted helminthiasis (STH), known as intestinal worms, dengue, river blindness and other diseases.
We are committed to sharing 80,000 chemical compounds from our Jump-stARter molecular library with the global research community to help collaborators accelerate treatment and prevention of neglected tropical diseases, along with TB, malaria and other diseases common in the developing world.
As part of the 2020 Paediatric HIV & TB: Rome Action Plan, Johnson & Johnson made the followign commitments within the HIV Treatment Plan:
To ensure innovation to improve the health of children by supporting the Clinton Health Access Initiative and Paediatric European Network for Treatment of AIDS PENTA in their commitment to accelerate development, registration and catalytic launch of Darunavir/ritonavir (DRV/r) 120/20mg optimal pediatric fixed dose combination and provide DRV API from 2021-2023
To support approaches that track access to paediatric patients and to continued transparency around our HIV & TB pediatric work.
To enhance collaboration and facilitate knowledge-sharing to promote development of new technologies to enhance effectiveness and acceptability of paediatric medicines, including long-acting injectables for infants and adolescents (Rilpivirine).
Established in 2020 by Johnson & Johnson’s Office of the Chief Medical Officer, the ethics-based framework for decision-making during the COVID-19 pandemic takes an evidence- and science-based, ethics- and values-driven approach to medical safety across all products in the Johnson & Johnson Family of Companies.
In 2020, alongside eight other companies working on investigational COVID-19 vaccines, we signed a #WeStandWithScience pledge committed to upholding the integrity of the scientific process as we work towards potential global regulatory filings and approvals of the first vaccines for COVID-19.
We pledge to only submit vaccines for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet the requirements of expert regulatory authorities.
In 2020, along with the Bill & Melinda Gates Foundation and 15 companies leading the ambitious pandemic research and development response effort, we signed a landmark Communiqué on Expanded Global Access commitment to ensure that people everywhere have access to the potential COVID-19 innovations under development, regardless of their income level. The agreement calls on governments, NGOs and other stakeholders to join the cause and help accelerate the end of the pandemic.
Each company agreed to follow a specific set of five principles outlined in the communiqué to help ensure global access to potential vaccines, therapeutics and diagnostics that could help accelerate the end of the pandemic.
The signing companies have agreed to expand the diversity of clinical trials to include lower-income settings and address the specific product characteristics that might be needed for use in those settings.
As part of its commitment, Johnson & Johnson also plans to allocate up to 500 million vaccine doses to lower income countries.
As part of the 2020 Paediatric HIV & TB: Rome Actoin Plan, we made several commitments within the 2020 TB Treatment Plan, including:
To ensure ongoing access to the 20mg bedaquiline tablet, which Johnson & Johnson, in partnership with Stop TB Partnership’s GDF Pediatric DR-TB Initiative, has already made available for over 130 countries, following U.S. Food and Drug Administration approval in May 2020.
To continue efforts in exploring additional clinical trial sites to ensure timely completion of a study investigating the use of bedaquiline in children below 5 years of age.
Recognizing it will take alignment of all our organizations to scale impact globally, we invite you to join the movement as a Steward of Inclusive Capitalism. Together, the collective action of Council members will contribute to a fairer, more inclusive and sustainable future for all people and our planet.